BRAF and melanoma: Research conducted by Acquaviva and collaborators demonstrated that heat shock protein 90 (Hsp90) inhibition by ganetespib in BRAFV600E-mutant melanoma cell lines leads to the loss of mutant BRAF expression and a reduction in both MAPK and PI3K/AKT signaling.